JP2024029261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024029261A5 JP2024029261A5 JP2024007290A JP2024007290A JP2024029261A5 JP 2024029261 A5 JP2024029261 A5 JP 2024029261A5 JP 2024007290 A JP2024007290 A JP 2024007290A JP 2024007290 A JP2024007290 A JP 2024007290A JP 2024029261 A5 JP2024029261 A5 JP 2024029261A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- isolated nucleic
- molecule
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 24
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000003827 upregulation Effects 0.000 claims 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 241001416177 Vicugna pacos Species 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810255570 | 2018-03-20 | ||
| CNPCT/CN2018/079631 | 2018-03-20 | ||
| CN201810255570.3 | 2018-03-20 | ||
| CN2018079631 | 2018-03-20 | ||
| PCT/CN2019/078515 WO2019179396A1 (en) | 2018-03-20 | 2019-03-18 | Novel anti-pd-1 antibodies |
| JP2020550711A JP7482031B2 (ja) | 2018-03-20 | 2019-03-18 | 新規の抗ｐｄ－１抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550711A Division JP7482031B2 (ja) | 2018-03-20 | 2019-03-18 | 新規の抗ｐｄ－１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024029261A JP2024029261A (ja) | 2024-03-05 |
| JP2024029261A5 true JP2024029261A5 (enExample) | 2024-08-15 |
Family
ID=67986701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550711A Active JP7482031B2 (ja) | 2018-03-20 | 2019-03-18 | 新規の抗ｐｄ－１抗体 |
| JP2024007290A Pending JP2024029261A (ja) | 2018-03-20 | 2024-01-22 | 新規の抗ｐｄ－１抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550711A Active JP7482031B2 (ja) | 2018-03-20 | 2019-03-18 | 新規の抗ｐｄ－１抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12030941B2 (enExample) |
| EP (1) | EP3768724A4 (enExample) |
| JP (2) | JP7482031B2 (enExample) |
| CN (2) | CN112236454B (enExample) |
| CA (1) | CA3093992A1 (enExample) |
| TW (1) | TWI829677B (enExample) |
| WO (1) | WO2019179396A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112236454B (zh) * | 2018-03-20 | 2022-09-13 | 上海药明生物技术有限公司 | 新型抗pd-1抗体 |
| CN112442122B (zh) * | 2019-09-04 | 2021-09-21 | 上海洛启生物医药技术有限公司 | 阻断型pd-1纳米抗体及其编码序列和用途 |
| CN114430746B (zh) * | 2019-09-25 | 2023-09-01 | 上海药明生物技术有限公司 | 新型抗pd-l1抗体 |
| KR20220070201A (ko) * | 2019-09-30 | 2022-05-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-pd-1 항체 및 이의 용도 |
| LT4157876T (lt) | 2020-05-26 | 2024-10-25 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antikūnai |
| CN114685655B (zh) * | 2020-12-28 | 2024-04-12 | 浙江纳米抗体技术中心有限公司 | Pd-1结合分子及其应用 |
| CN116829584A (zh) * | 2020-12-31 | 2023-09-29 | 浙江道尔生物科技有限公司 | 一种抗pd-1的单域抗体 |
| JP7694922B2 (ja) * | 2021-01-29 | 2025-06-18 | ミンフィ ファーマシューティカル （ハンチョウ） リミテッド | 抗原結合タンパク質およびその使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| CN106432494B9 (zh) | 2015-08-11 | 2022-02-15 | 广州誉衡生物科技有限公司 | 新型抗-pd-1抗体 |
| SG10201911035QA (en) * | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| CN106046162B (zh) * | 2016-06-21 | 2019-04-02 | 大庆东竺明生物技术有限公司 | 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用 |
| CN107474135B (zh) * | 2017-02-17 | 2020-08-18 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用 |
| AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| CN112236454B (zh) * | 2018-03-20 | 2022-09-13 | 上海药明生物技术有限公司 | 新型抗pd-1抗体 |
-
2019
- 2019-03-18 CN CN201980020380.6A patent/CN112236454B/zh active Active
- 2019-03-18 CN CN202211052114.1A patent/CN116333126A/zh active Pending
- 2019-03-18 CA CA3093992A patent/CA3093992A1/en active Pending
- 2019-03-18 WO PCT/CN2019/078515 patent/WO2019179396A1/en not_active Ceased
- 2019-03-18 TW TW108109186A patent/TWI829677B/zh active
- 2019-03-18 EP EP19771635.0A patent/EP3768724A4/en active Pending
- 2019-03-18 US US16/981,336 patent/US12030941B2/en active Active
- 2019-03-18 JP JP2020550711A patent/JP7482031B2/ja active Active
-
2024
- 2024-01-22 JP JP2024007290A patent/JP2024029261A/ja active Pending
- 2024-05-24 US US18/674,733 patent/US20240301067A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024029261A5 (enExample) | ||
| JP7001474B2 (ja) | 非免疫原性単一ドメイン抗体 | |
| JP2020124199A5 (enExample) | ||
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2020522261A5 (enExample) | ||
| JP2018121657A5 (enExample) | ||
| JP2018520993A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP7783350B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| US12325747B2 (en) | Human PD-L1 antibodies and methods of use therefor | |
| US12428489B2 (en) | Human PD-L2 antibodies and methods of use therefor | |
| RU2009117237A (ru) | Средство для профилактики/лечения рака | |
| JP2018522888A5 (enExample) | ||
| JP2017523984A5 (enExample) | ||
| US20250129167A1 (en) | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor | |
| JP2023506262A (ja) | 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法 | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JPWO2019179396A5 (enExample) | ||
| JP2020535825A (ja) | 細胞培養収穫物におけるジスルフィド結合還元を防ぐ方法 | |
| JPWO2023004326A5 (enExample) | ||
| NZ745564B2 (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| NZ745564A (en) | Antibodies specific to human poliovirus receptor (pvr) |